NEW CONCEPTS IN DRUG DISCOVERY AND DEVELOPMENT

Stopping or Reversing Disease Progression

Learn More
WE ARE ENDECE

ENDECE, LLC is a privately held biopharmaceutical company at the forefront of new drug discovery and development. Our library of proprietary compounds, invented and owned by ENDECE, was designed to stop disease by up-regulating specific biological pathways to stimulate a specific biological response. We focus on diseases whose treatment options are limited or non-existent and whose causes may not be well understood including Alzheimer’s disease, Neuropathic Pain and, demyelinating diseases such as, multiple sclerosis (MS), Transverse myelitis (TM) and osmotic demyelination syndrome (ODS) .

ENDECE was founded in 2006 and is located in Mequon, Wisconsin.

Learn More

LATEST NEWS

View All

ENDECE is preparing to take NDC-1308 into clinical studies. Our scientists describe the dual mechanism of action that allows NDC-1308 to induce remyelination for treating diseases such as neuromyelitis optica (NMO), multiple sclerosis (MS), and Alzheimer’s disease.

LEARN HOW ENDECE DISCOVERED NDC-1308 A COMPOUND WITH THE POTENTIAL TO REVOLUTIONIZE THE TREATMENT OF DEMYELINATING DISEASES INCLUDING MULTIPLE SCLEROSIS, TRANSVERSE MYELITIS AND OSMOTIC DEMYELINATION SYNDROME

Learn More

A SMALL MOLECULE INDUCES OLIGODENDROGENESIS LEADING TO MYELIN SHEATH REPAIR